Blue Bear Ventures

Unnatural Products Inc. is a biotechnology company based in Santa Cruz, California, focused on drug discovery through innovative technology. Founded in 2016, the company specializes in designing and developing a platform that utilizes artificial intelligence and computational biology techniques to create macrocyclic peptides. These peptides target intracellular protein interactions, addressing drug targets that are typically considered undruggable. By harnessing machine learning to optimize chemical synthesis, Unnatural Products aims to accelerate the drug discovery process, offering potential therapeutic strategies for a wide range of medical conditions. Through its unique approach, the company seeks to pioneer new treatments where traditional methods have fallen short.

ImpriMed, Inc. is a biotechnology company focused on providing personalized drug response prediction services for veterinary oncology. Established in 2017 and headquartered in Palo Alto, California, with an additional office in Seoul, South Korea, the company specializes in analyzing the drug responses of live cancer cells from pets, particularly in cases of lymphoma. By collecting genetic and cellular information from these cancer cells, ImpriMed develops precision medicine techniques that assist veterinary oncologists in selecting the most effective anticancer treatments for individual pets. This patient-derived database not only enhances treatment decisions for animals but also has the potential to translate insights into human oncology, ultimately aiding in the development of tailored cancer therapies for humans.

engageLively provides a cloud-based analytics service with a built-in visual application studio that helps firms organize, analyze, and visualize their data. They also provide arbitrary extensibility in hardware, software, memory, and storage.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.